Abstract:Cardiovascular diseases (CVD) cause significant global morbidity, mortality and public health burden annually. CVD alters richness, diversity, and composition of Gut microbiota along with RAS and histopathological differences. Present study explores Metformin role in mitigating doxorubicin induced cardiovascular toxicity/remodeling. Animals were divided into 4 groups with n=6: Group I (N. Control) free access to diet and water; Group II (MET. Control) on oral Metformin (250 mg/kg) daily; Group III (DOX. Control) alternate day intraperitoneal Doxorubicin (3 mg/kg) totaling 18 mg/kg; Group IV (DOX. MET. Control) received both daily oral Metformin (250 mg/kg) and alternate day Doxorubicin (3 mg/kg). Gut microbial analysis was made from stool before animals were sacrificed for biochemical and histopathological analysis. Significant alterations were observed in ɑ and β-diversity with new genus from Firmicutes , specifically Clostridia_UCG-014, Eubacterium ruminantium, and Tunicibacter , were prevalent in both the DOX. Control and DOX.MET groups. Proteobacteria , represented by Succinivibrio , were absent in all groups. Additionally, Parabacteroides from the Bacteroidia phylum was absent in all groups except the N. control. In the DOX.MET Control group, levels of Angiotensin II ( 7.75± 0.49 nmol/min, p<0.01) and Renin (2.60±0.26 ng/ml/hr) were significantly reduced. Conversely, levels of CK-MB, Fibrinogen, Troponin, CRP ( p < 0.0001), and TNFɑ (p < 0.05) were elevated. Histopathological examination revealed substantial cardiac changes, including Fibrinogen and fat deposition and eosinophilic infiltration, as well as liver damage characterized by binucleated cells and damaged hepatocytes, along with altered renal tissues in the DOX.MET.Control group. The findings suggest that MET. significantly modifies gut microbiota, particularly impacting the Firmicutes and Proteobacteria phyla. The reduction in Angiotensin II levels, alongside increased inflammatory markers and myocardial damage, highlights the complex interactions and potential adverse effects associated with MET therapy on cardiovascular health.

Reliability of Metformin's protective effects against doxorubicin-induced cardiotoxicity: a meta-analysis of animal studies

Metformin-mediated protection against doxorubicin-induced cardiotoxicity

Efficacy And Cardiotoxicity Of Liposomal Doxorubicin-Based Chemotherapy In Advanced Breast Cancer: A Meta-Analysis Of Ten Randomized Controlled Trials

Demystifying the Relationship Between Metformin, AMPK, and Doxorubicin Cardiotoxicity

[Metformin mitigates doxorubicin-induced cardiotoxicity via the AMPK pathway]

Systematic Evaluations of Doxorubicin-Induced Toxicity in Rats Based on Metabolomics

Early Transcriptional Changes in Cardiac Mitochondria During Chronic Doxorubicin Exposure and Mitigation by Dexrazoxane in Mice.

Cardioprotective effects of melatonin and metformin against doxorubicin-induced cardiotoxicity in rats are through preserving mitochondrial function and dynamics

Protective Effects of Dexrazoxane Against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study

Inhibition of multiple uptake transporters in cardiomyocytes/mitochondria alleviates doxorubicin-induced cardiotoxicity

Exploration the Mechanism of Doxorubicin-Induced Heart Failure in Rats by Integration of Proteomics and Metabolomics Data

Metformin Inhibits OCTN1- and OCTN2-mediated Hepatic Accumulation of Doxorubicin and Alleviates Its Hepatotoxicity in Mice.

Potential Biomarkers In Mouse Myocardium Of Doxorubicin-Induced Cardiomyopathy: A Metabonomic Method And Its Application

Metabolic Effects of Doxorubicin on the Rat Liver Assessed With Hyperpolarized MRI and Metabolomics

Protective effects of dimethyl itaconate in mice acute cardiotoxicity induced by doxorubicin

Metformin Protects against H2O2-Induced Cardiomyocyte Injury by Inhibiting the miR-1a-3p/GRP94 Pathway

Genistein alleviates doxorubicin‐induced cardiomyocyte autophagy and apoptosis via ERK/STAT3/c‐Myc signaling pathway in rat model

Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy

Metformin's dual impact on Gut microbiota and cardiovascular health: A comprehensive analysis

Mitigating Doxorubicin-Induced Cardiotoxicity through Quercetin Intervention: An Experimental Study in Rats

Meteorin-like protein attenuates doxorubicin-induced cardiotoxicity via activating cAMP/PKA/SIRT1 pathway